The ascension of Viagra initially ignited significant expansion in the medicinal sector, creating a image of guaranteed returns. However, investing in companies heavily reliant on blockbuster drugs like Sildenafil presents significant risks. Intellectual property expiry has caused off-brand competition, decreasing market portion and likely lowering

The recent surge in funding into boutique pharmaceutical companies, particularly those focusing on novel therapies and challenging drug development programs, has fueled what some are calling "High Stakeholder Pharma." While the potential for game-changing treatments and impressive returns is certain, the connected risks are also significant. Many o